Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. ====== Nuclear Receptor Binding Protein 1 ====== **Gene**: NRBP1 **Full name**: Nuclear Receptor Binding Protein 1 **Type**: Pseudokinase / Adaptor protein **Cellular location**: Involved in trafficking between the endoplasmic reticulum and Golgi apparatus ===== 𧬠Main Functions ===== * Regulates intestinal epithelial architecture via Wnt-responsive genes * Functions in cellular signaling despite lacking classic catalytic activity * Involved in protein homodimerization and intracellular transport * May regulate apoptosis and cell proliferation ===== š¬ Biomedical Relevance ===== === Cancer === * **Glioblastoma**: Promotes malignancy through PI3K/Akt pathway activation * **Triple-negative breast cancer**: Acts via Rac1/Cdc42 signaling through PāRex1 * **Colorectal cancer**: Overexpression linked to improved survival (via JNK pathway) * **Prostate and bladder cancer**: Associated with tumor progression === Non-oncological diseases === * **Gout**: Genetic variants increase susceptibility * **Triglycerides**: Implicated in lipid metabolism regulation === Viral infections === * Interacts with viral proteins: Dengue (NS3), HIVā1 (Gag) * Alters host membranes to promote viral replication ===== š Animal Model Studies ===== * Knockout mice are embryonically lethal (~E7.5) ā essential in early development ===== š§Ŗ Expression & Structure ===== * Highly expressed in: prostate, colon, brain, esophagus, testis * Contains a pseudokinase domain (lacks known enzymatic activity) * Several validated isoforms ===== Preclinical animal studies ===== In a [[preclinical animal study]]-[[rat model]] Xinxue Wei et al. from the Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi published in [[Biochemical Genetics Journal]] to investigate whether silencing the [[NRBP1]] gene using [[shRNA]] can enhance cognitive performance and reduce pathological hallmarks of [[Alzheimerās disease]] (AD) in a rat model induced by D-galactose and [[AlCl3]]. Silencing NRBP1 led to measurable improvements in spatial learning and memory, decreased [[Aβ1-42]] burden, and reduced [[amyloid plaque]] pathology in the [[hippocampus]]. The intervention restored performance close to non-AD control levels, suggesting that NRBP1 may play a critical role in [[Alzheimerās disease pathogenesis]] and could be a therapeutic target ((Wei X, Liu X, Ban Y, Li J, Huang R. Silencing [[NRBP1]] Gene with [[shRNA]] Improves [[Cognitive Function]] and Pathological Features in AD [[Rat]] [[Model]]. Biochem Genet. 2025 Jul 5. doi: 10.1007/s10528-025-11169-1. Epub ahead of print. PMID: 40616751.)) ---- **Critical Review:** This [[study]] explores a promising molecular target, NRBP1, in a standard AD animal model. The use of both behavioral (Morris water maze) and molecular (ELISA, Thioflavin-S, qPCR) assessments strengthens the internal consistency of the findings. However, it suffers from several critical limitations: 1. **Lack of Mechanistic Depth:** No molecular pathway analysis or downstream effectors of NRBP1 silencing are evaluated. Is NRBP1 affecting [[tau phosphorylation]], [[inflammation]], or synaptic signaling? 2. **Generic Model:** The use of D-gal/[[AlCl3]] lacks translational fidelity compared to genetic models (e.g., APP/PS1 [[mice]]). Its validity as a model of human AD pathology is limited. 3. **Short-Term Outcomes:** The study spans only 90 days, insufficient to capture chronic progression or long-term neurodegenerative effects. 4. **No Off-Target Assessment:** There is no report on potential off-target effects or systemic toxicity of the shRNA construct, which is critical for clinical translation. 5. **Statistical Rigor:** While [[P-value]]s are reported, no [[confidence interval]]s or effect sizes are provided, undermining the [[interpretability]] of the results. 6. **Redundancy in Control Groups:** Including both AD and AD+Neg control groups adds complexity without clear benefit, as both showed similar pathological profiles. **Final Verdict:** Although this is a decent preliminary [[preclinical study]] with encouraging results, its [[clinical relevance]] remains speculative due to model limitations and lack of mechanistic exploration. **Takeaway for Neurosurgeons:** This [[research]] is not yet [[practice-informing]] but hints at [[NRBP1]] as a possible neurodegenerative modulator. It's a reminder of the future importance of targeted molecular interventions in [[neurodegenerative disease management]]. **Bottom Line:** Promising, but early-stage; more mechanistic and translational work is needed. **Rating:** 4.5 / 10 ---- **Title:** Silencing NRBP1 Gene with shRNA Improves Cognitive Function and Pathological Features in AD Rat Model **Citation:** Wei X, Liu X, Ban Y, Li J, Huang R. *Biochem Genet*. 2025 Jul 5. doi:10.1007/s10528-025-11169-1. Online ahead of print. **Publication Date:** July 5, 2025 **Corresponding Author Email:** [[huangrongdrmed@163.com]] ---- **Blog Categories:** Experimental Research, Molecular Neuroscience, Alzheimerās Disease **Tags:** Alzheimerās, NRBP1, shRNA, rat model, cognitive function, amyloid plaques, gene silencing, neurodegeneration nuclear_receptor_binding_protein_1.txt Last modified: 2025/07/06 16:45by administrador